Qubigen retweeted
Qubigen won Gold in Medical at the 2026 AFR BOSS Most Innovative Companies Awards.
While the big agentic AI and frontier lab deals (Xaira’s X-Scientist, OpenAI’s Orchestra Bio acquisition, AZ–insitro) get the headlines, the hard constraint remains the same: most models still need either public data or private project data that leaves the lab.
Qubigen retweeted
Congrats to @DrJMMHall and the @QubigenOps @qubigen team for winning Gold in the AFR Most Innovative Companies 2026 Awards for their novel AI platform which enables AI for drug design without compromising stakeholder privacy or intellectual property.
afr.com/life-and-luxury/heal…
Qubigen retweeted
“Winning gold in the Medical category of the Financial Review BOSS Most Innovative Companies awards, Qubigen’s AI tool can learn from a trove of pharmaceutical lab investigations, all without copying or sharing the data.”
See link to the full article in the comments below 👇
Qubigen retweeted
🚨 🚨 On Wednesday Night, @qubigen was named the Gold winner in the Medical category of The Australian Financial Review AFR BOSS Most Innovative Companies Awards, taking out the top spot of this National competition! 🏆
This recognition reflects the groundbreaking work our team is doing to pioneer decentralised intelligence in drug discovery: building a platform that allows research labs to learn from their own high-value results without ever compromising, copying, or sharing raw data.
A huge congratulations 🥂 and thank you to our all-star team who made this possible: Sonya Diakiw (CSO), A/Prof Jun Zeng FRACI (CIO), Andrew Murphy (CTO), David Brooks (Operations Manager), Dr Tuc Van Nguyen (Senior Machine Learning Engineer), and Joshua Spender (Senior Software Engineer).
Special thanks to our board of directors for their continued support and backing, SYNthesis BioVentures, Prof. Andrew Wilks , Dr Amir Zalcenstein, Dr Fabio Turatti, James Roche, Chair Dr Michelle Perugini and our Corp Sec Rosemarie Singson.
Thank you to our advisors Matt Oristano, Trevor Thompson, Eric Hayes, and finally, to all the research and commercial partners who have worked with us and continue to collaborate with us on live projects.
Qubigen’s recent study on tailored federated AI for blood-brain-barrier permeability prediction has now been featured by Diagnostics World News in an article exploring why specialized AI systems are outperforming generic foundation models in life sciences.
diagnosticsworldnews.com/new…
🤖 Made with AI
Qubigen is pleased to report on a research collaboration with Dr. Srinivas Viswanathan and his team at Dana-Farber Cancer Institute. The project focuses on the discovery of novel small-molecule candidates for a rare and aggressive type of kidney cancer.
qubigen.com/post/qubigen-col…
Qubigen is excited to announce our participation in the upcoming BIO International Convention 2026 in San Diego, taking place from June 22-26, 2026.
qubigen.com/post/qubigen-to-…
Qubigen retweeted
Federated AI Engines for drug design enable secure collaboration, transcending institutional data firewalls. Qubigen's FedAIDD can leverage global data without actually moving or seeing it, to build the most intelligent, secure, disease-agnostic AI engines in drug design.
Qubigen and University of Melbourne Secure $496,348 Federal AEA Grant to Advance AI-Driven Drug Design
qubigen.com/post/qubigen-and…
Qubigen retweeted
. @qubigen is heading to San Francisco for J.P. Morgan Healthcare Week 2026 (11–15 January)! 🇺🇸 🇦🇺🐨
Proud to be part of the Australian Biotech Delegation, supported by Global Victoria. We’ll be actively partnering at BIO One-on-One, ABD Capital Connect sessions, and around Union Square.
Our Federated AI/ML platform is already accelerating drug design for pharma and CRO partners, collapsing hit-to-lead from years to weeks, securely and at fraction of the cost.
If you’re attending and interested in AI-enabled drug design or Series A discussions, let’s connect!
Reach me via BIO Partnering, ABD, or DM here.
Excited to build new bridges Down Under in the Bay Area.
In just over twelve months, Qubigen has evolved from an innovative idea into a validated, capital-efficient drug design platform, demonstrating that secure, Federated AI can deliver real scientific progress, commercial traction, and scalable value.
qubigen.com/post/one-year-of…
Qubigen to Attend JPM Week 2026 in San Francisco, Engaging Investors & Exploring Strategic Partnerships
qubigen.com/post/qubigen-to-…
Qubigen is pleased to announce the signing of an agreement with QIMR Berghofer, establishing a framework to accelerate the development of novel drug candidates targeting tumorigenesis and cancer progression.
qubigen.com/post/qimr-bergho…


















